The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery

Molecular Diagnosis and Therapy

Volumn 11, Issue 2, 2007, Pages 123-128

  Beinema, Maarten J ^a   De Jong, Petra H ^b   Salden, Har J M ^a   Van Wijnen, Merel ^c   Van Der Meer, Jan ^d   Brouwers, Jacobus R B J ^b  

^a DEVENTER HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c MEANDER MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; COUMARIN; CYTOCHROME P450 2C9; DICLOFENAC; IBUPROFEN; INDOMETACIN; LOW MOLECULAR WEIGHT HEPARIN; MELOXICAM; NADROPARIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROPYPHENAZONE; ROFECOXIB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TOTAL HIP PROSTHESIS;

EID: 34147120728     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256232     Document Type: Article

References (32)

1. O'Donnell M, Linkins LA, Kearon C, et al. Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular weight heparin following elective hip arthroplasty. Arch Intern Med 2003; 163: 1362-6
2. Strebel N, Prins M, Agnelli G, et al. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162: 1451-6
3. Hull RD, Pineo GF, MacIsaac S. Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res 2001; 101: 155-62
4. Samama CM, Vray M, Barré J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med 2002; 162: 2191-6
5. Douketis JD, Eikelboom JW, Quinlan DJ, et al. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Int Med 2002; 162: 1465-71
6. Palmer AJ, Koppenhagen K, Kirchhof B, et al. Efficacy and safety of low molecular weight heparin, unfractioned heparin and warfarin for thromboembolism prophylaxis in orthopaedic surgery: a meta-analysis of randomised clinical trials. Haemostasis 1997; 27 (2): 75-84
7. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review (a provisional record). Arch Intern Med 2003; 163: 901-8
8. Bates SM, Ginsberg JS. Bleeding after initiation of anticoagulant therapy for deep vein thrombosis [editorial]. Am J Med 1999; 107: 517-8
9. Roberts GW, Helboe T, Nielsen CBM, et al. Assessment of an age-adjusted warfarin initiation protocol. Ann Pharmacother 2003; 37: 799-803
10. O'Connell MB, Kowal PR, Allivato CJ, et al. Evaluation of warfarin initiation regimes in elderly inpatients. Pharmacotherapy 2000; 20: 923-30
11. Van den Bemt PMLA, Beinema MJ, Van Roon EN, et al. Initiation of oral anticoagulant therapy in orthopedic patients: an algorithm compared with routine dosing. Eur J Clin Pharmacol 2002; 58: 203-8
12. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8
13. Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000; 28: 1284-90
14. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001; 40: 587-603
15. Margaglione M, Colaizzo D, Dándrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000 Nov; 84 (5): 775-8
16. Verstuyft C, Morin S, Robert A, et al. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 2001; 11: 735-7
17. Aithal GP, Day CP, Kesteven JL, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirements and risk of bleeding complications. Lancet 1999; 353: 717-79
18. Brouwers JR, de Smet PA. Pharmacokinetic and pharmacodynamic drug interactions with non-steroidal and anti-inflammatory drugs. Clin Pharmacokinet 1994; 27: 462-85
19. Fijn R, Koorevaar RT, Brouwers JRBJ. Prevention of heterotopic ossification after total hip replacement with NSAIDs. Pharm World Sci 2003; 25: 138-45
20. Connelly CS, Panush RS. Should nonsteriodal ani-inflammatory drugs be stopped before elective surgery? Arch Intern Med 1991; 151: 1963-6
21. Visser LE, van Schaik RH, van Vliet M, et al. Allelic variants of cytochrome P450 2C9 modify the interaction between non-steroidal anti-inflammatory drugs and coumarin anticoagulants. Clin Pharmacol Ther 2005; 77: 479-85
22. Schaeffer MG, Plowman BK, Morreale AP, et al. Interaction of rofecoxib and celecoxib with warfarin. Am J Health Syst Pharm 2003; 60: 1319-23
23. Van Dijk KN, Plat AW, van Dijk AAC, et al. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and the role of CYP2C9 genotype. Thromb Haemost 2004; 91: 95-101
24. Rosendaal FR, Cannegieter SC, Van der Meer FJM, et al. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-9
25. Burian M, Grösch S, Tedeger I, et al. Validation of a new fluorogenical real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. J Clin Pharmacol 2002; 54: 518-21
26. Van der Meer FJM, Roosendaal FR, Vandenbroucke JP, et al. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993; 153: 1557-62
27. Azar AJ, Cannegieter SC, Deckers JW, et al. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996 May; 27 (6): 1349-55
28. Rieder M, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93
29. Bodin L, Versuyft C, Tregouet DA, et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-40
30. Schalekamp T, Brassé BP, Roijers JFM, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharm Ther 2006; 80: 13-22
31. MacDonald D, Bhalla P, Cass W, et al. Computerized management of oral anticoagulant therapy: experience in major joint arthroplasty. Can J Surg 2002; 45: 47-52
32. Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintanance dose of warfarin. Thromb Haemost 2004; 91: 87-9